Helicos BioSciencies, which is developing genetic analysis technologies for research and drug discovery uses, priced its IPO of 5.4 million shares at $9 on Thursday morning. The offer price represented a 36% discount to the midpoint of its originally proposed $13 to $15 price range. UBS Investment Bank was the lead underwriter on the deal. The stock is expected to begin trading on the NASDAQ under the ticker HLCS later today.
